Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Buoyancy continues across sectors
Wed, 23 Apr 01:30 pm

The Indian stock markets continued to scale higher in the last two hours of trade on the back of sustained buying activity across index heavyweights. Gains were led by stocks from the capital goods and consumer durable segments. The stocks from realty sector are, however, trading marginally lower.

The BSE-Sensex is trading higher by 105 points and the NSE-Nifty is trading higher by 27 points. The BSE Mid Cap index is trading up by 0.4% and the BSE Small Cap index is trading up 0.5%. The rupee is trading at 61.07 to the US dollar.

Stocks from Food & tobacco sector are trading mixed. While VST Industries and Ruchi Soya are trading higher, Britannia is trading down. As per a leading financial daily, GSK Consumer Healthcare has said in a filing to exchanges that multi-billion dollar deal amongst its parent GlaxoSmithKline Plc (GSK) and Swiss drug major Novartis is not likely to affect the company's Indian business unit. For instance, GSK and Novartis have agreed to form a joint venture wherein OTC (over-the-counter) division of Novartis would be combined with GSK's consumer business. The joint venture in which GSK will hold 63.5% is expected to have annual sales of about US$ 10 bn. According to the filing, the JV would exclude Indian GSK Consumer, where ownership would directly be held by GSK Plc. It may be noted that the parent, GSK has earlier increased its stake to 75% in the company through an open offer of Rs 64 bn.

In a move to strengthen the Indian banking system, RBI has barred Indian manufacturing and infrastructure companies from repaying their bank loans through ECB (external commercial borrowing) route availed at the bank's overseas branches or subsidiaries. The central bank's rationale for the same is that risk remains intact in the Indian banking system when ECB is availed from banks overseas branches. RBI has also cautioned the commercial banks from issuing guarantees or letter of credit to Indian companies' overseas JV or subsidiaries for purpose other than ordinary business course of that overseas arm. It has also sought out to effectively monitor the end use of funds to overseas arms of Indian companies. This is in order to bring down the unsystematic business risk of Indian banks.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Buoyancy continues across sectors". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.